Bausch Health Provides Update on RED-C Phase 3 Clinical Trials

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced the results of the global Phase 3 RED-C clinical program evaluating amorphous-rifaximin solid soluble dispersion (SSD) in adults with ...
Morningstar

Innovent's Mazdutide Shows Superiority in Glycemic Control with Weight Loss over Semaglutide in a Head-to-head Phase 3 Clinical Trial DREAMS-3

The proportion of participants achieving HbA1c < 7.0% and a ≥10% reduction in body weight from baseline was 48.0% in the mazdutide group and 21.0% in the semaglutide group DREAMS-3 is the world's ...

Biomed Industries Announces Phase 3 Trials of NA-931 Targeting Durable Weight Loss & Lean-Mass Preservation at JPM Week

Biomed Industries, Inc. Announces Two NA-931 Phase 3 Trials, Targeting Durable Weight Loss & Lean-Mass Preservation ...

FDA Granted Hopstem’s hNPC01 for Chronic Ischemic Stroke Approval to Enter Phase 2/3 Adaptive Pivotal Clinical Trial with Bridging Study

Hopstem Biotechnology Inc. (hereinafter referred to as "Hopstem"), a company dedicated to the development of induced ...
Ophthalmology Times

SpyGlass Pharma randomizes first patients in 2 phase 3 clinical trials of the BIM-IOL System

SpyGlass Pharma has randomized the first patients in its 2 registrational phase 3 clinical trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System) for the lowering of intraocular pressure (IOP) ...
The Manila Times

Kailera Therapeutics Announces First Participants Randomized in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide (KAI-9531)

Ribupatide (KAI-9531) aims to address critical need for greater weight loss, especially for people living with a BMI of 35 kg ...

Ainnocence and Phase Advance Enter Industry-First AI Collab to Reduce Drug Development Timeline and Clinical Trial Risk

The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development ...
Business Wire

Veradermics Completes Enrollment in its Phase 2/3 Clinical Trial of VDPHL01 for Male Pattern Hair Loss, Advancing Development of the Potential First-Ever Extended-Release Oral ...

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated, a dermatologist-founded, late clinical-stage biopharmaceutical company developing potentially first-in-class therapeutics for common ...

Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)

The study will be conducted in three phases. Part A is a Phase 2, open-label, semi-sequential dose-ranging portion of the study. Part B is the Phase 3, double-blind, randomized, placebo controlled ...